Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SomaDex
- Development stage
- Unknown
- Lead developer
- Dextech Solutions
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
SomaDex is a carbohydrate-drug conjugate (CDC) developed by DexTech Medical AB, utilizing the proprietary GuaDex platform. It consists of natural somatostatin-14 linked to a charge-modified dextran molecule. This design stabilizes the peptide, extending its half-life from approximately 3 minutes to 37 hours while maintaining high binding affinity for all five somatostatin receptor subtypes (SSTR1-5). SomaDex is primarily intended for the treatment of neuroendocrine tumors and acromegaly, as well as for the palliative treatment of metastatic castration-resistant prostate cancer (mCRPC). Clinical pilot studies have demonstrated a favorable safety profile and disease-stabilizing effects, including reductions in bone metastases in advanced prostate cancer patients.
- Other names
- Somatostatin-GuaDex
02
Targets
SSTR5 (Somatostatin receptor 5)SSTR3 (Somatostatin receptor 3)SSTR1 (Somatostatin Receptor Type 1)SSTR2 (Somatostatin receptor type 2)SSTR4 (Somatostatin receptor 4)
Beyond the preview
Go deeper on SomaDex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SomaDex.